- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
Key statistics
On Friday, Aethlon Medical Inc (AEMD:NAQ) closed at 0.5859, 58.18% above the 52 week low of 0.3704 set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.540 |
---|---|
High | 0.600 |
Low | 0.4594 |
Bid | 0.52 |
Offer | 0.5275 |
Previous close | 0.5501 |
Average volume | 14.67m |
---|---|
Shares outstanding | 5.05m |
Free float | 4.88m |
P/E (TTM) | -- |
Market cap | 2.07m USD |
EPS (TTM) | -5.03 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼